VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

Advanced Therapies Week 2022 | Highlights from Advanced Therapies Week 2022

Christopher Reardon, Dyno Therapeutics, Cambridge, MA, provides his highlights from Advanced Therapies Week 2022, including discussions relating to the development of fixed-bed bioreactors for adherent cell culture, which will enable the scaling-up of viral vector manufacturing. He additionally discusses improvements in the regulatory field, where authorities are streamlining the process for novel therapies, as well as improving the workplace environment for staff. This interview took place at Advanced Therapies Week 2022.

Disclosures

Christopher Reardon is an employee of Dyno Therapeutics.